Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE: AZD8931 plus paclitaxel vs paclitaxel in metastatic gastric or gastro-oesophageal junction cancer after first-line therapy
KCT0000401Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapitinib in gastric cancer (GC), esophagogastric junction cancer, sponsored by AstraZeneca. Planned start Apr 2012; status: not yet recruiting.
02
Drugs
sapitinib
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on KCT0000401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000401.